Efficacy and Safety of SHP465 at 6.25 mg in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-12 Years

Neuroscientific Insights, Rockville

University of Virginia Health System, Charlottesville

VA South Psychiatric & Family Services, Petersburg

Triangle Neuropsychiatry, Durham

Coastal Pediatric Associates, Charleston

Coastal Pediatric Associates, Mt. Pleasant

Institute for Behavioral Medicine, Smyrna

One Health Research Clinic, Inc., Norcross

Buford Family Practice, Buford

Clinical Neuroscience Solutions, Inc., Jacksonville

Clinical Neuroscience Solutions, Inc., Orlando

Clinical Associates of Orlando, Llc, Orlando

Power MD Clinical Research Institute, Hialeah

Acevedo Medical Group, Miami

Scientific Clinical Research Inc., North Miami

Care Research Center, Doral

Pharmacology Research, LLC, Miami

Harmonex Neuroscience Research, Dothan

Access Clinical Trials, Inc., Nashville

Kentucky Pediatric/Adult Research, Bardstown

Pedia Research, LLC, Owensboro

Family Practice Center of Wadsworth, Inc., Wadsworth

Ohio Pediatric Research Association, Dayton

Pedia Research, LLC, Evansville

Neurobehavioral Medicine Group, Bloomfield Hills

Conventions Psychiatry and Counseling, Naperville

St Charles Psychiatric Associates, Saint Charles

Psychiatric Associates, Overland Park

PEWMD, PA, ARCSM, PLLC, PRP, Inc., Little Rock

IPS Research Company, Oklahoma City

Houston Clinical Trials, LLC, Houston

El Campo Clinical Trials, El Campo

Children's Clinic, League City

Advanced Clinical Research Inc., Meridian

Peninsula Research Associates - CRN, Rolling Hills

Riverside Medical Clinic, Riverside

Advanced Research Center, Anaheim

Northwest Clinical Research Center, Bellevue

Mid-Columbia Research, Richland

GA Psychiatric Services, LLC., Atlanta

University of Texas, San Antonio